ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR)
today announced that
Andrew Blight
, Chief Scientific Officer, will
present at the Jefferies 2014 Global Healthcare Conference in London on
Wednesday, November 19 at 9:20am GMT.
A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com,
or you may use the link:
http://wsw.com/webcast/jeff86/acor
Please log in approximately 5 minutes before the scheduled time of the
presentations to ensure a timely connection. An archived version of this
webcast will be available until December 19, 2014 on the Investors
section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing therapies
that improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS), as demonstrated by an
increase in walking speed.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy. This
pipeline addresses a range of disorders including post-stroke deficits,
Parkinson’s disease, epilepsy, stroke, peripheral nerve damage, spinal
cord injury, neuropathic pain, and heart failure.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statements
This press release includes
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of
historical facts, regarding management's expectations, beliefs, goals,
plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause
actual results to differ materially, including our ability to
successfully market and sell Ampyra in the U.S.; third party payers
(including governmental agencies) may not reimburse for the use of
Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of
Ampyra or from our other research and development programs, including
Plumiaz, and CVT-301, or any other acquired or in-licensed programs; we
may not be able to complete development of, obtain regulatory approval
for, or successfully market Plumiaz, CVT-301 or any other products under
development; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable terms;
the occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our
collaboration partner Biogen Idec in connection therewith; competition;
failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party
intellectual property licenses needed for the commercialization of our
products; failure to comply with regulatory requirements could result in
adverse action by regulatory agencies; and the ability to obtain
additional financing to support our operations. These and other risks
are described in greater detail in Acorda Therapeutics' filings with the
Securities and Exchange Commission. Acorda may not actually achieve the
goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of the
date hereof, and Acorda disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this release.
Source: Acorda Therapeutics